Literature DB >> 14533785

Temporal course of upregulation of Na(v)1.8 in Purkinje neurons parallels the progression of clinical deficit in experimental allergic encephalomyelitis.

Matthew J Craner1, Yuko Kataoka, Albert C Lo, Joel A Black, David Baker, Stephen G Waxman.   

Abstract

Multiple sclerosis (MS) is recognized to involve demyelination and axonal atrophy but accumulating evidence suggests that dysregulated sodium channel expression may also contribute to its pathophysiology. Recent studies have demonstrated that the expression of Na(v)1.8 voltage-gated sodium channels, which are normally undetectable within the CNS, is upregulated in cerebellar Purkinje cells in experimental allergic encephalomyelitis (EAE) and MS, and suggest that the aberrant expression of these channels contributes to clinical dysfunction by distorting the firing pattern of these neurons. In this study we examined the temporal pattern of upregulation for Na(v)1.8 mRNA and protein in chronic relapsing EAE by in situ hybridization and immunocytochemistry, respectively. Our results demonstrate a positive correlation between disease duration and degree of upregulation of Na(v)1.8 mRNA and protein in Purkinje neurons in chronic-relapsing EAE. The progressive deterioration in clinical baseline scores (i.e. in clinical scores during remissions) is paralleled by a continued increase in Na(v)1.8 mRNA and protein expression, but temporary worsening during relapses is not associated with transient changes in Na(v)1.8 expression. These results provide evidence that the expression of sodium channel Na(v)1.8 contributes to the development of clinical deficits in an in vivo model of neuroinflammatory disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14533785     DOI: 10.1093/jnen/62.9.968

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  7 in total

1.  Abnormal Purkinje cell activity in vivo in experimental allergic encephalomyelitis.

Authors:  Carl Y Saab; Matthew J Craner; Yuko Kataoka; Stephen G Waxman
Journal:  Exp Brain Res       Date:  2004-04-29       Impact factor: 1.972

2.  Temporal pattern of plasma membrane calcium ATPase 2 expression in the spinal cord correlates with the course of clinical symptoms in two rodent models of autoimmune encephalomyelitis.

Authors:  Arnaud Nicot; Michael Kurnellas; Stella Elkabes
Journal:  Eur J Neurosci       Date:  2005-05       Impact factor: 3.386

3.  Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis.

Authors:  G Grasselli; S Rossi; A Musella; A Gentile; S Loizzo; L Muzio; C Di Sanza; F Errico; G Musumeci; N Haji; D Fresegna; H Sepman; V De Chiara; R Furlan; G Martino; A Usiello; G Mandolesi; D Centonze
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

4.  Purkinje cell loss in experimental autoimmune encephalomyelitis.

Authors:  Allan MacKenzie-Graham; Seema K Tiwari-Woodruff; Gaurav Sharma; Cynthia Aguilar; Kieumai T Vo; Lauren V Strickland; Laurie Morales; Boma Fubara; Melanie Martin; Russell E Jacobs; G Allan Johnson; Arthur W Toga; Rhonda R Voskuhl
Journal:  Neuroimage       Date:  2009-07-06       Impact factor: 6.556

5.  IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain.

Authors:  John S Tzartos; Matthew J Craner; Manuel A Friese; Karen B Jakobsen; Jia Newcombe; Margaret M Esiri; Lars Fugger
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

6.  A-type FHFs mediate resurgent currents through TTX-resistant voltage-gated sodium channels.

Authors:  Yucheng Xiao; Jonathan W Theile; Agnes Zybura; Yanling Pan; Zhixin Lin; Theodore R Cummins
Journal:  Elife       Date:  2022-04-20       Impact factor: 8.713

7.  Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis.

Authors:  John S Tzartos; Manuel A Friese; Matthew J Craner; Jackie Palace; Jia Newcombe; Margaret M Esiri; Lars Fugger
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.